Provided by Tiger Trade Technology Pte. Ltd.

Tango Therapeutics Inc.

23.88
+0.37001.57%
Pre-market: 23.74-0.1450-0.61%09:12 EDT
Volume:2.49M
Turnover:59.34M
Market Cap:4.04B
PE:-28.43
High:24.36
Open:23.95
Low:23.48
Close:23.51
52wk High:34.39
52wk Low:6.25
Shares:169.00M
Float Shares:142.96M
Volume Ratio:1.27
T/O Rate:1.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8400
EPS(LYR):-0.8746
ROE:-21.34%
ROA:-12.99%
PB:3.94
PE(LYR):-27.31

Loading ...

Top Midday Gainers

MT Newswires Live
·
Mar 06

Stock Track | Tango Therapeutics Soars 5.10% Intraday on Better-Than-Expected Q4 Results and New Clinical Collaboration

Stock Track
·
Mar 05

Tango Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 05

Stock Track | Tango Therapeutics Plunges 7.11% in Pre-Market as Q4 Results Show No Revenue, Widened Loss

Stock Track
·
Mar 05

Erasca, Tango Therapeutics Partner on Phase 1/2 Trial for Combination Cancer Therapy

MT Newswires Live
·
Mar 05

Tango Therapeutics Q4 net loss widens

Reuters
·
Mar 05

Earnings Flash (TNGX) Tango Therapeutics Posts Q4 Loss $0.29 a Share

MT Newswires Live
·
Mar 05

BRIEF-Erasca And Tango Therapeutics Enter Into Clinical Collaboration To Evaluate Combination Of ERAS-0015 And Vopimetostat

Reuters
·
Mar 05

Tango Therapeutics posts FY 2025 collaboration revenue of USD 62.4 million +108.2%

Reuters
·
Mar 05

Erasca Inc: Co Will Supply Eras-0015 Free of Charge, and Tango Will Be Trial Sponsor

THOMSON REUTERS
·
Mar 05

Erasca Inc: Each Company Will Retain Commercial Rights to Their Respective Compound

THOMSON REUTERS
·
Mar 05

Erasca and Tango Therapeutics Enter Into Clinical Collaboration to Evaluate Combination of Eras-0015 and Vopimetostat

THOMSON REUTERS
·
Mar 05

BRIEF-Tango Therapeutics Q4 Basic EPS USD -0.29

Reuters
·
Mar 05

Tango Therapeutics Inc: Cash Position of $343 Mln as of December 31, 2025, With Runway Into 2028

THOMSON REUTERS
·
Mar 05

Tango Therapeutics President, R&D Crystal Adam Disposes of Common Shares

Reuters
·
Feb 28

Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Tango Therapeutics (TNGX)

TIPRANKS
·
Feb 27

Tango Therapeutics weakness an ‘over reaction,’ says Stifel

TIPRANKS
·
Feb 27

Earning Preview: Tango Therapeutics Inc. this quarter’s revenue is expected to decrease by 93.56%, and institutional views are bullish

Earnings Agent
·
Feb 26

Tango Therapeutics Inc : Mizuho Initiates Coverage With Outperform Rating; Target Price $19

THOMSON REUTERS
·
Feb 23